Assignment Task

Introduction

Abdominal Aortic Aneurysms (AAA) present a critical medical challenge, necessitating a profound exploration of treatment strategies to enhance patient outcomes and optimize resource utilization. AAA, characterized by the abnormal enlargement of the aorta, requires a nuanced understanding of the most effective interventions.

This report employs a combined approach of Decision Tree and Markov models to delve into the intricate landscape of cost-effectiveness in AAA treatment. The decision problem at hand revolves around selecting the most beneficial approach for patients, considering both clinical effectiveness and financial implications. Open Surgical Repair (OSR) stands as the conventional method, while the emergence of Endovascular Aneurysm Repair (EVAR) introduces a compelling alternative. Furthermore, the analysis extends to two novel treatment options, TxA and TxB, necessitating a thorough investigation of their cost-effectiveness compared to established methods. The primary objective is dual-fold: firstly, a meticulous comparison of the cost-effectiveness of OSR and EVAR; and secondly, an assessment of the cost-effectiveness of two innovative treatments, TxA and TxB. Employing Decision Tree analysis for short-term consequences and a Markov model for long-term outcomes over a 20-year horizon, this evaluation aims to provide actionable insights for healthcare decision-makers, unraveling the complexities of AAA treatment alternatives.

Methods

The chosen methods for evaluating the cost-effectiveness of AAA treatment options demonstrate a robust and comprehensive approach, combining a two-stage model with Decision Tree and Markov components. The model structure integrates a short-term Decision Tree, capturing outcomes within 30 days, and a long-term Markov model spanning 20 years with 1-year cycles. This bifurcated approach allows for a nuanced understanding of both immediate and extended consequences, providing a holistic view of the treatment landscape. The inclusion of diverse health states, encompassing no complications, stroke, myocardial infarction (MI), renal failure, congestive heart failure (CHF), and mortality, ensures a thorough exploration of patient outcomes. Furthermore, recognizing rupture as an additional adverse consequence for EVAR, TxA, and TxB adds a layer of complexity, aligning the model with real-world clinical scenarios.

The assumptions made, such as the exclusion of health consequences and discounting in the short-term model, are rationalized by the 30-day time horizon. Given the focus on immediate outcomes, this approach simplifies the analysis, emphasizing the acute phase without prematurely attributing long-term consequences. The decision to use a 20-year time horizon and 1-year cycles in the Markov model aligns with the chronic nature of AAA and facilitates a comprehensive evaluation of the evolving health states over an extended period. Data sources contribute significantly to the credibility of the model. Drawing from three reputable journal articles, namely Hayes et al., Blackhouse et al., and Sousa et al., provides a solid foundation for the model structure. These articles not only offer insights into the global experience but also contribute specific regional perspectives, enhancing the generalizability of the findings. Additionally, the incorporation of a starter model with probabilities, costs, and utilities, along with specific trial data for complications following OSR, ensures a tailored and nuanced representation of the diverse treatment options.

The methods employed in this evaluation demonstrate a thoughtful and comprehensive approach. The combination of Decision Tree and Markov models, incorporation of diverse health states, and utilization of data from reputable sources collectively contribute to a robust framework for assessing the cost-effectiveness of AAA treatment options. The chosen assumptions align with the specificities of the research question, and the reliance on high-quality literature ensures the validity and reliability of the model`s foundation.

Model Structure

The short-term Decision Tree

The decision tree model in this analysis provides a structured framework for evaluating short-term consequences of AAA treatments. It bifurcates into branches representing various outcomes, including complications and mortality, within a 30-day time horizon. This intuitive visual representation allows for a systematic exploration of the immediate consequences of Open Surgical Repair (OSR), Endovascular Aneurysm Repair (EVAR), and hypothetical treatments (TxA and TxB). Each of these treatments has consequences that can be incurred and the possibility of postoperative complications, and I used a short-term decision tree model to calculate the Costs and Expected Costs for each scenario. The decision tree aids in quantifying the probabilities and associated costs, offering a concise depiction of the short-term economic and clinical implications for decision-makers in the realm of AAA treatment.

The long-term Markov model

The long-term Markov model employed in this analysis extends over a 20-year horizon, utilizing 1-year cycles to simulate the evolving health states for AAA patients. It incorporates six possible health states, including complications and death, providing a dynamic representation of the chronic nature of AAA treatment outcomes. The model enables a detailed exploration of the transition probabilities between health states, considering complications, rupture, and conversion to Open Surgical Repair (OSR). I analysed the data by building four long-term models of the possible disease transitions that can occur in OSR, EVAR, TxA, and TxB, respectively.

Discussion

An evaluation of AAA treatment options has elucidated important insights into their relative cost-effectiveness. The analysis highlights that endovascular aneurysm repair (EVAR) is a more cost-effective option than open surgical repair (OSR), with a lower cost per quality-adjusted life year (QALY). This suggests that while both options incur high costs, EVAR presents a relatively more favorable economic profile. However, compared with traditional OSR, EVAR has better postoperative recovery effects. Because the surgical intervention is smaller than OSR, recovery is faster. A robust evaluation will involve comparing the cost-effectiveness of TxA and TxB to established benchmarks for OSR and EVAR. Among them, TxB has the highest number of QALYs and the highest cost.

The model structure I chose combines a two-stage approach with decision trees and Markov components, which has the advantage of being able to comprehensively capture both short- and long-term consequences. However, the assumption of ignoring health consequences and discounts in the short-term model, while justified by the 30-day time horizon, also introduces limitations. A short-term focus may oversimplify the complexities of health outcomes and discounting, potentially affecting overall cost-effectiveness conclusions. Utilizing three reputable journal articles ensures a solid foundation for the model`s structure, but inherent differences in healthcare systems across regions may introduce uncertainty. Reliance on trial data on post-OSR complications is a strength, but may introduce bias if the trial population differs significantly from the broader patient population.

The National Institute for Health and Care Excellence (NICE) faces a challenging decision-making environment given the cost-effectiveness results. Although EVAR appears to be more cost-effective than TxB, both interventions have extremely high costs per QALY, raising questions about their value. The decision-making process should weigh economic and clinical outcomes, recognizing budget constraints and the need for optimal resource allocation. The implications of the findings extend to consideration of willingness-to-pay (WTP) thresholds. Since EVAR is more cost-effective than TxB, the decision on which treatment to recommend depends on the acceptable WTP threshold. EVAR`s extremely high ICER challenges its economic viability under traditional cost-effectiveness benchmarks. NICE should critically assess whether the benefits of EVAR are worth the substantial additional costs, particularly when compared with the relatively more cost-effective OSR.

The discussion synthesizes the complexities of cost-effectiveness analysis and highlights the nuances of treatment options for AAA. Comparative analyzes of OSR and EVAR elucidate their economics, while evaluations of new treatment options highlight the importance of obtaining specific cost-effectiveness metrics. The strengths and weaknesses of the chosen method, coupled with considerations of data sources and uncertainties, determine the depth and reliability of the findings. Its influence extends to NICE`s decision-making advice, which urges a thoughtful balance between cost-effectiveness and clinical efficacy, and a rigorous review of willingness-to-pay thresholds to ensure that health resources are allocated wisely.